Nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
== Column preparation == A column is prepared by packing a solid adsorbent into a cylindrical glass or plastic tube. The size will depend on the amount of compound being isolated. The base of the tube contains a filter to hold the solid phase in place. The filter is either a plug made of cotton or glass wool, or a glass frit. A solvent reservoir may be attached at the top of the column.
==== Criticism ==== David Handelsman has criticized terminology and understanding surrounding AAS in many publications. According to Handelsman, the pharmaceutical industry attempted to dissociate the so-called "androgenic" and "anabolic" effects of AAS in the mid-20th-century in order to create non-masculinizing anabolic agents that would be more suitable for use in women and children. However, this effort was unsuccessful and was abandoned by the 1970s. This was related to the subsequent discovery of a single androgen receptor (AR) mediating the effects of AAS in both muscle and reproductive tissue. In addition, it was related to misinterpretation of flawed animal androgen bioassays that had been employed to distinguish between androgenic or virilizing effects and anabolic or myotrophic effects (i.e., the Hershberger assay involving the unrepresentative levator ani muscle). In actuality, all AAS have essentially similar AR-mediated effects, even if some AAS may vary in potency in certain tissues like skin, hair follicles, and prostate gland based on their susceptibility to 5α-reduction (and associated metabolic amplification, inactivation, or lack thereof). Per Handelsman, the terms "anabolic steroid" and "anabolic–androgenic steroid" are obsolete, meaningless, and falsely distinguish these agents from androgens when there is no physiological basis for such distinction. It has also been noted that the use and distinction of the concepts "anabolic" and "androgenic", as well as the term "anabolic–androgenic steroid", are oxymoronic.
Arthur Brouhard Robinson (born March 24, 1942) is an American biochemist, conservative activist, prominent climate change denier, and politician who served as the Oregon State Senator from the 2nd District from 2021 to 2025. He was the five-time Republican nominee for the United States House of Representatives for Oregon's 4th congressional district. A former faculty member of the University of California, San Diego, Robinson now runs a privately funded laboratory known as the Oregon Institute of Science and Medicine in Cave Junction, Oregon, a newsletter called Access to Energy, and publishes the Robinson Self-Teaching Home School Curriculum. As the Republican nominee for the Fourth District in Oregon, Robinson ran and lost to Democratic incumbent Peter DeFazio in five consecutive elections: 2010, 2012, 2014, 2016, and 2018. He served as chairman of the Oregon Republican Party from August 2013 to February 2015.
Sources: en.wikipedia.org
== Safety == Adverse reactions, rarely serious, may occur from each component of the MMR vaccine. Ten percent of children develop fever, malaise, and a rash 5–21 days after the first vaccination; and 3% develop joint pain lasting 18 days on average. Older women appear to be more at risk of joint pain, acute arthritis, and even (rarely) chronic arthritis. Anaphylaxis is an extremely rare but serious allergic reaction to the vaccine. One cause can be egg allergy. In 2014, the FDA approved two additional possible adverse events on the vaccination label: acute disseminated encephalomyelitis (ADEM), and transverse myelitis, with permission to also add "difficulty walking" to the package inserts. A 2012 IOM report found that the measles component of the MMR vaccine can cause measles inclusion body encephalitis in immunocompromised individuals. This report also rejected any connection between the MMR vaccine and autism. Some versions of the vaccine contain the antibiotic neomycin and therefore should not be used in people allergic to this antibiotic. The number of reports on neurological disorders is very small, other than evidence for an association between a form of the MMR vaccine containing the Urabe mumps strain and rare adverse events of aseptic meningitis, a form of viral meningitis. The UK National Health Service stopped using the Urabe mumps strain in the early 1990s due to cases of transient mild viral meningitis, and switched to a form using the Jeryl Lynn mumps strain instead.
In chemistry, a molecule or ion is called chiral () if it cannot be superposed on its mirror image by any combination of rotations, translations, and some conformational changes. This geometric property is called chirality (). The terms are derived from Ancient Greek χείρ (cheir) 'hand'; which is the canonical example of an object with this property. A chiral molecule or ion exists in two stereoisomers that are mirror images of each other, called enantiomers; they are often distinguished as either "right-handed" or "left-handed" by their absolute configuration or some other criterion. The two enantiomers have the same chemical properties, except when reacting with other chiral compounds. They also have the same physical properties, except that they often have opposite optical activities. A homogeneous mixture of the two enantiomers in equal parts, a racemic mixture, differs chemically and physically from the pure enantiomers. Chiral molecules will usually have a stereogenic element from which chirality arises. The most common type of stereogenic element is a stereogenic center, or stereocenter. In the case of organic compounds, stereocenters most frequently take the form of a carbon atom with four distinct groups attached to it in a tetrahedral geometry. Less commonly, other atoms like N, P, S, and Si can also serve as stereocenters, provided they have four distinct substituents (including lone pair electrons) attached to them.
Weapons pour into the country in the form of Russian help to the MPLA. Tanks, armoured troop carriers, rockets, mortars, and smaller arms have already been delivered. The situation remains exceptionally fluid and chaotic, and provides cover for SWAPO [insurgents] out of South West Africa. Russian help and support, both material and in moral encouragement, constitutes a direct threat. To South African Minister of Defence P.W. Botha, it was evident that the MPLA had gained the upper hand; in a memo dated late June 1975, he observed that the MPLA could "for all intents and purposes be considered the presumptive ultimate rulers of Angola...only drastic and unforeseeable developments could alter such an outcome." Skirmishes at the Calueque hydroelectric dam, which supplied electricity to South West Africa, gave Botha the opportunity to escalate the SADF's involvement in Angola. On 9 August, a thousand South African troops crossed into Angola and occupied Calueque. While their public objective was to protect the hydroelectric installation and the lives of the civilian engineers employed there, the SADF was also intent on searching out PLAN cadres and weakening FAPLA.
nascent In the process of being synthesized; incomplete; not yet fully processed or mature. The term is commonly used to describe strands of DNA or RNA which are actively undergoing synthesis during replication or transcription, or sometimes a complete, fully transcribed RNA molecule before any post-transcriptional modifications have been made (e.g. polyadenylation or RNA editing), or a peptide chain actively undergoing translation by a ribosome.
Sources: en.wikipedia.org
Aminopeptidases are enzymes that catalyze the cleavage of amino acids from the N-terminus (beginning), of proteins or peptides. They are found in many organisms; in the cell, they are found in many organelles, in the cytosol (internal cellular fluid), and as membrane proteins. Aminopeptidases are used in essential cellular functions, and are often zinc metalloenzymes, containing a zinc cofactor. Aminopeptidases occur in both water-soluble and membrane-bound forms and can be found both in various cellular compartments and in the extracellular environment (outside of cells). Their broad substrate specificity, their ability to strongly bind to their targets, allows them to remove beginning N-terminal amino acids from almost all unsubstituted oligopeptides. For instance, Aminopeptidase N (AP-N) is particularly abundant in the brush border membranes of the kidney, the small intestine, and the placenta, and is also found in the liver. AP-N is involved in the final digestion of peptides generated from the hydrolysis (cleaving) of proteins by gastric and pancreatic proteases. Some aminopeptidases are monomeric, and others are found as assemblies of relatively high mass (50 kDa) subunits. cDNA sequences are available for several aminopeptidases and a crystal structure of the open state of human endoplasmic reticulum aminopeptidase 1 is available.
=== Post‑Fight bonus increases === Beginning in January 2026, starting with UFC 324, the UFC increased its post‑fight bonus structure, raising Performance of the Night and Fight of the Night awards from $50,000 to $100,000, and introducing additional $25,000 bonuses for any knockout or submission not selected among the standard four post‑fight awards.
"It hurt me greatly to call it [the radio station] Radio Nacional Islas Malvinas, and I used to try to avoid referring to Port Stanley as Puerto Argentino. I called it 'the capital' or the 'largest settlement on the island'"
== Randomised controlled trial (RCT) == The AIDA diabetes simulator has been tested out in a pilot randomised controlled trial (RCT). The protocol used for the RCT was described a priori in the medical / diabetes literature. The study sought to assess whether diabetes educational teaching sessions using the AIDA simulator led to better outcomes than similar diabetes educational teaching sessions without a computer. The study was run at the Ospedale di Marino, near Rome, in Italy by an independent diabetologist / endocrinologist – unconnected with the simulator's development. Twenty-four volunteers (12 male and 12 female) with type 1 diabetes of more than 6-years duration, aged 19–48 years, who gave written informed consent, were randomly assigned to one of two study groups, each receiving different teaching interventions. Group A was exposed to the AIDA diabetes simulator, while Group B (the control group) received conventional lessons with slides and transparencies. Six lessons were held for each group (one per week). At the beginning and end of the study all subjects had their glycated hemoglobin (HbA1c) measured. The subjects also carefully documented the incidence of any symptomatic hypoglycaemic episodes ('hypos'), whether mild (sweating, dizziness), moderate (nausea, vomiting), or severe (requiring assistance). The results seem encouraging. HbA1c levels in Group A dropped significantly from 7.2% to 6.4% after lessons with the diabetes simulator (p = 0.01).
=== Response to injury === Myomesin has also been shown to play a role in injury response and expression. It was previously thought that myosin chaperones were the first alert of sarcomere damage, but recent studies show a flux of expression the gene myomesin1a much earlier than that of the myosin, suggesting that there is a myomesin-dependent injury response pathway in striated muscles. Additionally, it is thought that this gene could be used as an enhanced biomarker for sarcomere damage compared to the current biomarker, muscle creatine kinase (CKM). When tested in vivo in zebrafish, myom1a expression was displayed much earlier than creatine kinase, indicating that the latter is less specific to muscle diseases. This supports the use of myomesin assays for detection of muscular pathologies earlier than the current practices.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.